Key Drivers
- Strong Liquidity
- Persistent Losses
- Rising Leverage
AIAI Summary
REPL has shifted from a binary pre-commercial biotech to a high-risk launch story after TUDRIQEV's accelerated approval, but investors should demand early net-sales, reimbursement, and adoption proof before chasing a rally that already prices in meaningful success amid heavy cash burn and likely future dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Rising Leverage
REPL has strong liquidity but faces severe losses, persistent cash burn, weakening equity, and an elevated 13.35x book-value valuation.
Price Behavior
Key Price Behavior Insights:
- •Strong monthly rally
- •Key resistance test
- •Pullback risk
REPL remains bullish over the last month, but reclaiming $15.50–$15.60 and breaking $15.88 is needed for continuation, while a drop below $14.05 would weaken the setup.
Sharp jump from $5.50 to $11.20 suggests a possible corporate action or data adjustment
Sentiment & News
Key News Insights:
- •FDA Disclosure Concerns
- •BLA Rejection
- •Share Price Collapse
Replimune faces sustained securities litigation over alleged inadequate FDA-related disclosures for RP1, following a BLA rejection and steep shareholder losses.
The legal overhang and reported value destruction are likely to weigh heavily on REPL investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings